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Abstract 10 
Organs-on-chips (OoCs), also known as microphysiological systems or “tissue chips” (the terms 11 
are synonymous), have garnered substantial interest in recent years owing to their potential to 12 
be informative at multiple stages of the drug discovery and development process. These 13 
innovative devices could provide insights into normal human organ function and disease 14 
pathophysiology, as well as more accurately predict the safety and efficacy of investigational 15 
drugs in humans. Therefore, they are likely to become useful additions to traditional preclinical 16 
cell culture methods and in vivo animal studies in the near term, and in some cases, 17 
replacements for them in the longer term. In the last decade, the OoC field has seen dramatic 18 
advances in the sophistication of biology and engineering, in the demonstration of physiological 19 
relevance, and in the range of applications. These advances have also revealed new challenges 20 
and opportunities, and expertise from multiple biomedical and engineering fields will be 21 
needed to fully realize the promise of OoCs for fundamental and translational applications. This 22 
Review provides a snapshot of this fast-evolving technology, discusses current applications and 23 
caveats for their implementation, and offers suggestions for directions in the next decade. 24 
  25 
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[H1] Introduction 26 
Drug development is slow and costly, driven mainly by high attrition rates in clinical trials1. 27 
Although remarkable increases in our understanding of the molecular underpinnings of human 28 
diseases and our ability to model in vivo cell, tissue and organ-level biology have been made 29 
over the past three decades, the number of US Food and Drug Administration (FDA)-approved 30 
drugs per billion US$ spent on research and development has actually decreased monotonically 31 
since 19502. Drug development needs new approaches, paradigms and tools to reverse these 32 
trends and thus deliver on the promise of science for patients2. 33 
 34 
Although animal models have contributed enormously both to our understanding of physiology 35 
and disease, and to the development of new medicines, researchers have long been aware of 36 
the frequent discordance between animal and human studies and therefore the need for 37 
modeling and testing platforms that would be more predictive of human responses3,4. Indeed, 38 
drug candidates may be terminated for lack of efficacy in animals, or discovery of hazards or 39 
toxicity in animals that might not be human-relevant. Despite significant developments in 40 
computational and in vitro biology and toxicology in the last two decades, currently over 80% of 41 
investigational drugs fail in clinical testing, with 60% of those failures due to lack of efficacy and 42 
another 30% due to toxicity5. 43 
 44 
To address some of these issues and offer alternative tools for preclinical stages, early “cell 45 
culture analogs”6,7 were explicitly designed to culture mammalian cells in linked chambers 46 
perfused with a recirculating tissue medium, or “blood surrogate”. Following on from these 47 
models came a “heart-lung micromachine”, integrating a lung cell culture model with a cardiac 48 
device to assess the effects of drugs and therapeutics delivered to the human lung by aerosol 49 
on cardiac function and toxicity in vitro. This first “lung-on-a-chip” research was published in 50 
20108 and set the stage for organs-on-chips (OoCs, synonymously known as “tissue chips” or 51 
microphysiological systems (MPS)) — microdevices engineered to contain (human) cells and 52 
tissues and to model or mimic organ structures, functions, and reactions to biological 53 
conditions, stressors or compounds. 54 
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 55 
The dramatic expansion of the OoC field in the past decade has been made possible by the 56 
convergence of multiple previously disparate technologies, including induced pluripotent stem 57 
cells (iPSCs) and mixed cell culture capabilties, genome editing, 3D printing, sophisticated cell 58 
sensors, microfluidics, and microfabrication engineering, which led to the demonstration that 59 
dynamic culture conditions significantly influence the physiological maturation and function of 60 
in vitro systems. Tissue chips offer promise in, for example, modeling multiple organs and 61 
tissues from individual donors of both healthy and disease dispositions, and investigating the 62 
responses of these tissues to environmental perturbations and therapeutics with known or 63 
unknown mechanisms of action. Worldwide investment from scientific funding bodies (Box 1) 64 
has enabled the development of a multitude of 3D tissue models, from relatively simple single 65 
cell type organoids to complex multi-cell type, multi-organ microfluidically-integrated systems 66 
(Table 1). Consortia, committees and workshops have emerged in Europe, the US and Asia to 67 
discuss state-of-the-science aspects of OoCs (Box 1). 68 
 69 
In this Review, we will cover how OoCs have evolved over the last decade into a potentially 70 
transformational translational science paradigm. OoCs could impact drug discovery and 71 
development by offering novel tools for disease modeling and understanding, as well as 72 
providing alternative – and potentially more predictive – methods for assessment of toxicity 73 
and efficacy of promising new compounds and therapeutics. There are clear opportunities for 74 
this technology to provide more rapid, cost-effective, and accurate information on human 75 
diseases and drugs being developed to treat them, providing insights for academic, 76 
biopharmaceutical, and regulatory scientists that were previously not possible. We will explain 77 
how OoCs can model healthy and diseased phenotypes and discuss the promise of linked 78 
platforms for the creation of “body on chip” systems. Importantly, we will cover the limitations 79 
of OoCs and discuss how defining the context of use of OoC platforms is critical for their 80 
continued development. Current considerations and challenges will be detailed, and our 81 
predictions for the ongoing era of tissue chip research presented. 82 
 83 
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[H1] Key features of organs-on-chips 84 
OoCs are bioengineered microdevices that recapitulate key functional aspects of organs and 85 
tissues. While there is wide diversity in the specific designs of each platform, OoCs range from 86 
devices the size of a USB thumb drive to larger systems that reflect multiple linked organs 87 
within the footprint of a standard 96-well laboratory plate. All OoC platforms have three critical 88 
and defining characteristics: the three-dimensional nature and arrangements of the tissues on 89 
the platforms; the presence and integration of multiple cell types to reflect a more 90 
physiological balance of cells (such as parenchymal, stromal, vascular and immune cells); and 91 
the presence of biomechanical forces relevant to the tissue being modeled (such as stretch 92 
forces for lung tissues or hemodynamic shear forces for vascular tissues). One way that 93 
biomechanical forces can be introduced to model fluid flow across the tissues is to include 94 
microfluidic channels in the systems to deliver and remove cell culture media, and remove 95 
associated cell metabolites and detritus. Organoids – another type of multi-cellular 3D tissue 96 
model replicating some aspects of in vivo organ structure and function – are not classified as 97 
OoCs due to their production through stochastic self-organization (rather than specific cell 98 
seeding and growth protocols) and lack of cytoarchitectural structure (rather than provision of 99 
scaffolding or specially-shaped culture chambers)9. 100 
 101 
Table 1 highlights some specifics of how OoCs differ from two-dimensional cell cultures. Each 102 
platform design, from 2D plates to complex 3D engineered systems, has advantages and 103 
disadvantages. Therefore, the selection of a particular platform will depend on the context of 104 
its use, such as the characteristics of the assays and their readouts. One key advantage for OoC 105 
platforms is the ability to control cellular and specific tissue architecture to emulate chemical 106 
gradients and biomechanical forces. This allows precision control over the biochemical and 107 
cellular milieu to model in vivo-like environments and responses. Other advantages include the 108 
ability to vascularize or perfuse tissues, either with inclusion of self-assembling endothelial cells 109 
that form perfusable lumens, or by use of microfluidic channels that act as engineered 110 
vasculature, bringing nutrients and fluidic flow to cells within culture chambers. Also, the ability 111 
to incorporate real-time tissue function sensors such as microelectrodes or optical microscopy 112 
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markers (for example fluorescent biomarkers) allows for monitoring cell health and activity. 113 
Figure 2 illustrates some of the diversity of OoC systems and shows how they can provide a 114 
wide range of data outcomes that can be employed during drug development. 115 
 116 
[H3] Common considerations and challenges  117 
Before OoC platforms are implemented, careful consideration of a large number of variables 118 
and challenges is needed to create and validate systems that reflect the context of use and 119 
desired outcomes. Although not mututally exclusive, these challenges can be categorised as 120 
either biological and technical. 121 
 122 
[H2] Biological considerations and challenges 123 
[H3] Defining context of use: When creating OoC systems, bioengineers are essentially reverse-124 
engineering human cellular systems; that is, taking apart and analyzing the components of the 125 
biological system, identifying the key aspects and components needed for function, and using 126 
these findings to reconstitute the functional system10. Reverse-engineering human tissues and 127 
physiological systems is complicated due to an often-incomplete understanding of the 128 
composition and interplay of any given tissue and system. Therefore, rather than attempt to 129 
comprehensively model a complex system, it may be more useful to engineer simple tissues 130 
that can still give relevant and useful answers for the specific field of study. For example, it may 131 
be more beneficial to use discrete vascularized brain organoids11-13 when modeling 132 
glioblastoma, psychiatric disorders or developmental neurotoxicity than to create a complex 133 
multi-organ system with cardiovascular, lymphatic and glymphatic components. However, a 134 
multi-organ system could provide novel pathological insights into disease mechanisms for 135 
disorders or toxicities that require interactions of more than one organ. 136 
 137 
Currently, OoCs can model certain aspects of a tissue but no single system completely 138 
recapitulates a fully functional and integrated human tissue, let alone an organ. Rather, systems 139 
are designed to model key aspects of a tissue – or its most characteristic features – to mimic 140 
the morphological and functional phenotype of interest; where the phenotype being evaluated 141 
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depends on the question being asked. Despite the emerging diversity of OoC platforms (see 14 142 
for a recent review), identifying the base platform choice that can provide answers to the 143 
research problem(s) in question remains challenging for end-users. 144 
 145 
[H3] Cell sourcing: Regardless of system complexity, one universal issue faced by OoC 146 
developers and users is renewable cell sourcing (Box 2). Choosing the appropriate cells for a 147 
system is partly based on the context-of-use of the platform but also often based on the 148 
availability of a particular cell source from commercial entities or from primary donors, which 149 
each have advantages and disadvantages. Increasingly, iPSCs or adult stem cells sourced from 150 
mass production of tissue organoids are seen as the answer to the lack of available primary 151 
cells15, and iPSCs have some compelling advantages. For example, iPSCs offer an almost 152 
unlimited source of cells, and generating isogenic cell lines from them means that all tissues in 153 
multi-OoC platforms could be from the same donor16,17, thereby addressing a key source of 154 
variability. However, to date, the phenotype of many iPSC-derived differentiated cells such as 155 
cardiomyocytes is immature, and protocols for differentiation and maturation are non-156 
standardized and can be difficult to reproduce (Box 2). 157 
 158 
[H3] Cell scaffolds: In addition to understanding a tissue’s composition, engineering a tissue 159 
requires understanding the functional interplay of cell types and the effect of the scaffold or 160 
extracellular matrix [G] (ECM) on the function of the cellular architecture18. OoCs may use 161 
decellularized scaffolds or seed cells within natural or synthetic hydrogels [G] to create an 162 
environment conducive to cell growth, but the ECM composition and three-dimensional 163 
arrangement affect cell survival, morphology and polarity19-21 and so must be carefully chosen 164 
and engineered to promote the formation of appropriate tissue characteristics. The choice of 165 
the ECM material must be considered – hydrogels (networks of polymers that swell with water 166 
application) are a widely used material due to their biocompatibility, support for cell adhesion, 167 
and similarities to many soft tissues and in vivo ECM, but may be difficult to engineer and lack 168 
standardized protocols for creation. The complexities of modeling even relatively simple tissues 169 
with few cell types can be exponentially magnified when including vascularization, innate or 170 
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adaptive immune responses, and the frequent and often large variability in tissue sources 171 
between donors/suppliers/batches. Recent advances in bioengineering allow new possibilities 172 
for incorporation of biosensors into systems via the ECM. For example, incorporation of 173 
fluorescent microgels containing peptides that are cleaved in the presence of specific 174 
enzymes22 offers the opportunity to use ECM for real-time readouts of OoC assays. 175 
 176 
[H3] Linking multiple platforms: Linking multiple OoCs into multi-organ systems is not trivial and 177 
requires consideration of aspects such as biological (allometric) scaling, maintenance of sterility 178 
when building or connecting tissue modules, use of a common medium, incorporation of 179 
bubble traps, and control of varying flow rates23,24. Additionally, a number of organs and tissues 180 
are necessarily missing from even the most complex series of linked OoCs, necessitating the 181 
need to account for missing organs. For example, how can a linked platform model important 182 
diurnal or endocrine fluctuations – which affect cell and drug metabolism25,26 – if tissues 183 
producing or responding to those cues are absent? One solution has been the creation of 184 
complex engineered ‘microformulators’ to formulate, deliver and remove culture medium at 185 
defined time intervals, simulating the function of missing organ(s)27. However, this remains an 186 
ongoing challenge. 187 
 188 
[H3] Universal medium: Each tissue requires an adequate supply of specific nutrients and 189 
growth factors relevant for that tissue, so for linked OoC tissue systems, a key challenge is 190 
providing this kind of universal cell culture medium or “blood mimetic”. So far, approaches to 191 
address this issue have included scaling mixtures of culture media and engineering endothelial 192 
barriers. For example, circulating a 50:50 mix of liver-specific and kidney-specific media in a 193 
linked liver-kidney system recently enabled the nephrotoxic metabolites of aristolochic acid to 194 
be determined28. However, as the number of linked systems increases, the success of the 195 
scaling solution decreases, as every tissue ends up with a suboptimal culture medium, which 196 
will impact the function and therefore physiological relevance of the system. Approaches for 197 
linking systems may involve: creating single-pass or recirculating systems of culture medium 198 
that can be replenished or modified over time29,30; or engineering platforms that allow culture 199 
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of tissues in individual modules but provide access to a circulating ‘blood surrogate’ medium by 200 
inclusion of synthetic or endothelial barriers between tissue modules and the circulating 201 
medium31-33. Some researchers have approached the universal medium problem by providing 202 
tissues with appropriate individual support through variation of the surface chemistry of the 203 
platform or scaffold on which cells are cultured (e.g. by silanes), while circulating a general 204 
serum-free medium to introduce fluidic flow to the system34,35. 205 
 206 
[H2] Technical considerations and challenges 207 
[H3] Platform design: The characteristics of the assays that are intended to be run on an OoC 208 
must be considered early in the design phase or when choosing a particular platform. Many 209 
chips incorporate microfluidics, which can supply tissues with the nutrients and factors needed 210 
for function and introduce important biomechanical forces such as the shear forces 211 
experienced by cells adjacent to vasculature. However, microfluidic designs must carefully 212 
model the resulting forces on the tissues because channel diameters, corners, and input/output 213 
ports can influence flow rate and therefore tissue performance36. Ports for inflow and outflow 214 
must be designed to maintain the sterility needed for cell culture while still allowing for culture 215 
changes. Also, ‘bubble traps’ may need to be incorporated, as a bubble in a microfluidic channel 216 
can completely block all flow37. 217 
 218 
Modeling biomechanical forces is appropriate in certain tissues; for example, stretch forces for 219 
lung alveolar tissues38. An elegant solution from an early lung-on-a-chip introduced vacuum 220 
channels running alongside a porous membrane onto which lung alveolar cells were seeded on 221 
one side and lung endothelial cells on the other. Rhythmic application of the vacuum caused 222 
stretching and relaxation of the cell-lined membrane and mimicked the biomechanical forces 223 
associated with breathing8. This design has been adapted for many other tissues including 224 
gut39, heart40, blood-brain barrier41 and kidney glomerulus42, highlighting how a simple design 225 
concept can be useful for multiple applications. 226 
 227 
The assays of interest for each platform will ultimately dictate platform design. For example, 228 
chips replicating cardiac function likely need to allow access by a microscope and be fabricated 229 
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of optically clear materials to allow imaging of cardiac twitching 43,44. Liver chips modeling 230 
oxygen zonation may make use of microfluidic flow rates to create differing zones of oxygen 231 
saturation45. Neural or muscular (cardiac or skeletal) platforms should incorporate multi-232 
electrode arrays [G] , or more microscale assays such as patch clamping or voltage clamping to 233 
provide readouts of cell activity40. Inclusion of biosensors such as fluorophores can allow real-234 
time readouts of cell function; for example, metabolism, activity, or activation of certain 235 
molecular pathways46. A recent automated multi-tissue organ system integrated an impressive 236 
array of on-chip sensors including electrochemically activated immunobiosensors attached to 237 
physical microelectrodes, mini-microscopes, in addition to optical pH, oxygen and temperature 238 
monitors47. This technical feat highlights the ongoing engineering advances that are enabling 239 
real-time non-invasive monitoring of OoC microenvironments. 240 
 241 
[H3] Platform fabrication: Although hydrogels and other scaffolds can help structure the 242 
internal cellular architecture of an OoC, the fabrication materials for the chip itself must be 243 
carefully considered. Every material for platform fabrication has a surface chemistry that affects 244 
how cells, fluids and compounds bind or absorb into the material. For example, 245 
polydimethylsiloxane (PDMS) is a silicon-based organic polymer that is widely used for platform 246 
fabrication because it is affordable and easy to work with via soft lithography methods, 247 
allowing for fast prototyping and easy iterative design change, and it creates flexible, 248 
biocompatible, optically clear platforms that allow modeling of biomechanical forces and real-249 
time tissue imaging. However, PDMS is gas permeable (which can be an advantage or 250 
otherwise) and has a high absorbance for small hydrophobic molecules48. Therefore, PDMS 251 
becomes problematic for drug studies as the PDMS-based platform itself can absorb a large 252 
amount of the drug, or the resulting factors released from the cells may be leached from the 253 
effluent. There is also a risk of cross-contamination for chambers or channels adjacent to each 254 
other. So, mitigatory approaches for PDMS OoCs include treatment or coating of the polymer-255 
based surfaces of the device to prevent cell adhesion or drug loss49-52. Alternative materials for 256 
chip fabrication include glass, silicon, and thermoplastics such as cyclic olefin coplastic (COC) 257 
and poly(methyl) methacrolate (PMMA), with the material choice often being a trade-off 258 
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between the needs of the platform versus the availability, affordability or fabrication feasibility 259 
of the materials.  260 
 261 
Regardless of fabrication material choice, all OoC platforms require careful characterization of 262 
adsorption/absorption profiles. Additionally, the biocompatibility of the materials to be used 263 
must be considered and profiled, as unexpected toxicities could appear when repurposing 264 
materials for platform fabrication53. 265 
 266 
[H1] Organs-on-chips for toxicity assessment 267 
Toxicity and unknown safety of exposure to human tissues are large sources of failures of 268 
potential drug candidates, and accounted for 40% of losses based on failure data from four 269 
large pharmaceutical companies5. Traditionally, key individual tissues that are targeted for 270 
toxicity assessments include liver, heart, kidney, vasculature, and brain. Methods of assessing 271 
toxicity in these organs often use high-throughput but simple cell culture assays, which cannot 272 
replicate a complex systemic response to a compound, or animals, which can model complex 273 
responses but may not provide an accurate prediction of effects in humans. 274 
Pharmacokinetic/pharmacodynamic (PK/PD) modelling [G] and physiologically-based 275 
pharmacokinetic (PBPK) modeling [G] can be used to predict the absorption, distribution, 276 
metabolism and excretion (ADME) of chemical substances in the body. However, these 277 
modeling methods rely on data from other model systems and detailed anatomical and 278 
physiological information where it is available. Animal studies are crucial for studying systemic 279 
and longer-term effects in full biological systems, but the similarities and differences in 280 
comparative physiology to humans can be anywhere on the spectrum between directly 281 
translational to confounding or even completely unknown. Indeed, extreme and sometimes 282 
tragic examples of the difficulty in translating from animals to humans can be seen in high 283 
profile phase I clinical trial failures, although these events are thankfully rare 54,55. These failures 284 
were seen either during the ‘first-in-human’ phase54 or during the dose escalation phase. The 285 
drawbacks of current toxicity profiling highlight the intricacies of the translational process from 286 
cell culture, to animals, and ultimately to humans, which can place clinical trial volunteers at 287 
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high-risk however carefully planned and executed a trial is. Additionally, there is a growing need 288 
to predict the toxicity of novel modalities such as biologics, oligonucleotides and large 289 
molecules (MW > ~900 Da) that are challenging or impossible to assess in standard animal 290 
models. OoCs may have advantages for these modality-specific assessments by allowing 291 
modeling of complex human responses in tightly-controlled in vitro systems that may be linked 292 
to model organ crosstalk 56 and can be designed for specific contexts of use 57. 293 
 294 
Single-tissue OoCs offer an alternative way to approach toxicity assessments of potential 295 
compounds in various complex human 3D tissues58. In 2D liver cultures, hepatic cell line 296 
cultures poorly represent primary human hepatocytes59, and the latter cells rapidly de-297 
differentiate over 24 hours60, limiting their usefulness in evaluating either subacute or chronic 298 
exposure effects and systemic toxicities. An example of how OoCs could address such issues is a 299 
recently developed 3D liver OoC system that can maintain healthy cell cultures for over 28 days 300 
(Table 2) and mimic the in vivo environment of the liver (to include hemodynamic flow, oxygen 301 
zonation and inclusion of immune components)61,62, which opens new pathways for 302 
ADME/toxicity studies. Oxygen zonation in this liver platform was achieved by controlling the 303 
flow rate of medium through the platform to create zones of differing oxygen tension, and 304 
coupling computational modeling of this tension to direct temporal and spatial monitoring of 305 
oxygen-sensitive dyes in the system45. This highlights how use of biomechanical forces and 306 
direct experimental assays from real-time biosensor readouts can be combined to provide 307 
powerful tools for accurate replication of clinically-relevant toxicity profiles. Separation of the 308 
sinusoid (vascular channel) and hepatic compartment by a porous membrane allows 309 
physiologically-relevant addition of drugs, immune cells and other factors to the model 62. 310 
Another recent study comparing a liver on a chip from rat, dog and human cell sources 311 
elegantly showed species-specific differences in hepatotoxicity, highlighting the importance of 312 
using human-specific cells for certain assays, while confirming the validity of the use of non-313 
human models for others63 (Table 2). 314 
 315 
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For the heart, which is another important target organ of toxicity, a number of heart-on-a-chip 316 
systems have been developed that model the complex matrices of cardiomyocytes, (cardiac) 317 
fibroblasts, endothelial cells and vasculature that interact in vivo in a highly ordered manner, 318 
which can be easily perturbed by drugs, drug-drug interactions, or off-target side effects. Since 319 
in vitro screens are now an integral part of drug development to characterize cardiac safety 320 
liabilities, the current heart-on-a-chip systems are useful as they model human responses to 321 
injury (Table 2), and show appropriately aligned sarcomeres, rhythmically synchronized beating 322 
patterns, and physiologically relevant resting membrane potentials44,64-67. Other structures in 323 
the heart, such as cardiac valves, have been bioengineered to assess the off-target cardiac side 324 
effects of dopamine/serotonin production/reuptake influencing-drugs, such as pergolide, which 325 
are used in clinical treatment for psychiatric disorders such as Parkinson’s disease68. However, a 326 
large problem with all cardiac OoC systems currently using iPSC-derived tissues is the fetal 327 
phenotype of most resulting cardiomyocytes69,70. Despite this, recent advances using electrical 328 
and mechanical stimulation to ‘train’ the developing cells or cardiac “organoid” growth in fatty 329 
acid-based culture medium and inclusion of other relevant cell types seems to encourage a 330 
significantly more mature phenotype71-74, further expanding the potential use for OoC in the 331 
cardiotoxicity field. 332 
 333 
Other important tissues for toxicity profiling include those from the kidney, gut, and lung. 334 
Developmental toxicity assays, including neurotoxicity, are also relevant for many exposure 335 
studies. OoC models of the kidney (nephron and proximal tubules) can be used to model 336 
readouts relevant for nephrotoxicity profiling such as filtration, reabsorption, transport of 337 
various molecules, and action of protein transporters75-78. Indeed, a kidney-on-a-chip system 338 
was used to elucidate that polymyxin-B nephrotoxicity may be caused by the cholesterol 339 
biosynthesis pathway, highlighting how OoCs could not only be used to test the safety of novel 340 
chemical molecules but also shed light on toxicological pathways of FDA-approved molecules78 341 
(Table 2). Gut-on-chip systems can model certain aspects of the bioavailability and activity of 342 
drugs, by creating in vitro intestinal epithelia and exposing these tissues to relevant 343 
biomechanical forces, such as flow and peristalsis79,80. Inclusion of immune and microbiome 344 
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factors become critical for true human relevance, both of which by themselves are huge areas 345 
of research, although there is progress being made in inclusion of these in both organoid81 and 346 
microfluidic systems82-85. For example, the “HuMix” model to recreate human-microbial 347 
crosstalk allows researchers to investigate the causal relationships between the gastrointestinal 348 
microbiota and certain human diseases, but could also be used in toxicology and 349 
pharmacokinetic studies82. Toxicity profiling of inhaled substances can benefit from lung-on-a-350 
chip models that can recapitulate the air-liquid interface of the lung alveoli8,86 and model 351 
effects such as exposure to bacteria, drug-induced pulmonary edema and cigarette smoke87. 352 
Developmental neurotoxicity can be modeled in platforms containing 3D neural tissues. For 353 
example, in a study that used RNA-Seq readouts from neural constructs exposed to 60 drugs of 354 
known toxicity, a predictive model based on linear support vector machines had over 90% 355 
accuracy in predicting the toxicological impact of ‘blinded unknown’ compounds13, highlighting 356 
the potential power of these types of 3D models for predictive toxicology. Other developmental 357 
toxicological vulnerabilities have been assessed using placenta-on-a-chip models that can 358 
recapitulate the ability of compounds to cross or affect the maternal-fetal barrier 88,89. 359 
Readouts of vascular-related toxicity may be critical for therapeutics, and vascular networks on 360 
OoCs have been used to investigate vascular toxicity with chemotherapeutics29,90, and risk 361 
factors for complications such as thrombosis from monoclonal antibody treatments 91.  362 
 363 
Finally, linked multi-organ systems could expand OoC applications into organ interactions and 364 
systemic toxicity profiling, and these are discussed further in section 6. 365 
 366 
[H1] Disease modeling on a chip 367 
In addition to being useful as tools for understanding toxicity in human tissues, OoCs also offer 368 
ways to model disease states in vitro, thereby allowing mechanistic investigation not only of 369 
disease pathologies but also of the efficacy and potential off-target effects of therapeutic 370 
interventions. The potential enhanced understanding of human disease physiology from 371 
modeling diseases on OoCs could help address the high attrition rates of promising compounds 372 
seen during both lead optimization and clinical development stages due to lack of efficacy 5,92. 373 
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 374 
[H2] Stem cells and tissue chips – powerful partners 375 
While many OoCs have been developed to model disease phenotypes using primary or cell line 376 
sources, the increasing use of iPSCs, plus the novel option of using the mass production of 377 
organoid technology as a way to source adult stem cells in biomedical research, has also led to 378 
the increased development of an array of diseases-on-chips including: cardiac (atrial and 379 
ventricular) myopathies72,93,94; asthma95; vascular abnormalities96; polycystic kidney disorders97; 380 
as well as neural disorders – including ones mimicking aspects of neurodegenerative and 381 
psychiatric disorder phenotypes98,99 – and rare pediatric diseases such as Hutchinson-Gilford 382 
Progeria Syndrome 100. However, a limitation associated with using stem cell-derived cells in 383 
OoCs include difficulties in producing an adequate number of mature, differentiated cells with 384 
the necessary purity for many tissues (for more see Box 2). 385 
 386 
Despite these current limitations, one early example of the power of iPSCs’ use in OoCs, 387 
coupled with genome editing technologies, investigated the rare childhood pediatric 388 
cardiomyopathy Barth Syndrome. Stem cell derived-cardiac tissues from patient donors were 389 
created and modeled on ‘muscular thin films’, which replicated the disordered sarcomeric 390 
organization and weak contraction properties seen in the disease101. Using genome editing 391 
techniques to ‘correct’ the faulty TAZ gene in the iPSC-derived cardiomyocytes, mitochondrial 392 
abnormalities underlying the disease were identified. These results highlight the potential use 393 
of OoCs as models for the critical stages of target validation where the creation of multiple 394 
tissue types from the same patient, and the generation of isogenic control tissues by genetic 395 
editing methods for any number of genetically-based diseases, can enable detailed and specific 396 
mechanistic studies for these disorders102. 397 
 398 
[H2] “You-on-a-chip” for common and rare diseases 399 
Disease modeling on OoCs could contribute to the development of precision medicine. OoCs 400 
modeling angiogenesis103, tumor growth104, and intra- and extravasation105,106, have all 401 
contributed to the development of vascularized and metastatic breast cancer models107-110. The 402 
treatment of patient-derived tumors on chips with chemotherapeutics enabled treatment 403 
OoC - NRDD 2019 16
comparison and optimization108, which is a step towards using this technology for precision 404 
medicine. Tumor-on-a-chip platforms have also helped parse out the mechanistic effects of 405 
different chemotherapeutic agents on the resulting ‘microtumors’90. Other tumor-on-a-chip 406 
models include neural glioblastoma111, renal cell carcinoma112, as well as lung113, pancreatic114, 407 
colorectal115, ovarian116, prostate117, and cervical118 cancer, among many other types. 408 
 409 
While many of these models were created with cancer cell lines, an obvious and powerful 410 
opportunity arises when patient-derived primary or iPSC-derivatives are seeded onto OoC 411 
models, creating “patient-on-a-chip” models. This could inform the stratification of cancer 412 
patient populations into subpopulations that respond optimally to different chemotherapeutic 413 
regimens or cocktails, but could also lead to development of “you-on-a-chip” for rare cancer 414 
patients or those with unusual etiologies. Communities with rare diseases could benefit 415 
tremendously from the opportunity to recreate these pathologies on chips (see 119 for a 416 
review). For example, patient-derived pancreatic ductal epithelial cells can be used to create a 417 
pancreas-on-a-chip to potentially understand the cystic fibrosis transmembrane conductance 418 
regulator protein and its role in insulin secretion120. If iPSC protocols become available for 419 
pancreatic cell creation – a current challenge with promising progress in the field121 – then 420 
modeling of an individual with cystic fibrosis on a chip becomes possible, which could prove 421 
useful to understand the high risk of diabetes and glucose imbalance in this population. 422 
 423 
[H2] Synergistic engineering to combine 3D models 424 
Both OoC and organoid 3D models have strengths and limitations (Table 1), but innovative ways 425 
to combine the technologies and introduce related ones such as 3D bioprinting – so-called 426 
‘synergistic engineering’122– adopts strengths from multiple 3D bioengineering fields to create 427 
reliable predictive tissue models with the opportunities for higher throughput screening (see 123 428 
for a comprehensive review). For example, both organoids (which self-organize into three 429 
dimensions) and bioprinted tissues (where cells are deposited in a specific manner) can be 430 
seeded or printed in multi-well plates with media flow and inclusion of other biomechanical 431 
forces, creating platforms with multi-tissue components that are amenable to larger scale 432 
commercial production. An example of these combined technologies includes vascularized 433 
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organ ‘buds’ that can be perfused by a common medium124 and bioprinting of endothelialized 434 
myocardium in a microfluidic perfusion bioreactor125. In the case of the latter, multiple 435 
bioengineering techniques were combined to create an innovative tool for predicting 436 
cardiovascular toxicity. First, endothelial cells were encapsulated into bioprinted microlattices 437 
to allow formation of an endothelial vascular bed, after which cardiomyocytes were introduced 438 
forming a myocardial tissue with good alignment to the bioprinted vascular bed. Finally, 439 
inclusion of the tissue construct into a microfluidic bioreactor allowed continuous vascular 440 
perfusion and real-time monitoring of cardiac contraction phenotypes for up to 2 weeks. 441 
 442 
As with all disease models, the demonstration that these 3D tissue models effectively mimic the 443 
behaviors of the disease, as well as the responses to therapeutic drugs, in vivo is critical for 444 
their validation. 445 
 446 
[H1] 6. Creating a “Body on a Chip” 447 
Linkage of multi-organ tissue systems is of clear benefit to model complex organ-organ 448 
interactions and inform PK/PD and PBPK modeling, ADME profiling, and quantitative systems 449 
pharmacology (QSP) and other computational modeling. Over the last decade, many efforts 450 
have been undertaken to integrate multiple systems and overcome the challenges associated 451 
with this (see 126 for a review). Indeed, US governmental funding from the Defense Advanced 452 
Research Project Agency (DARPA) was specifically allocated to create and link 10 organ systems 453 
(see Related links) that were viable for 28 days into a single ‘body on a chip’ as part of broader 454 
efforts by the US National Institutes of Health (NIH), FDA and DARPA to fund the development 455 
of tissue chips to advance regulatory sciences (see Related links). From this funding, two recent 456 
publications showed how a 10-organ “physiome on a chip” combined with QSP computational 457 
approaches could model distribution of in vitro pharmacokinetics and endogenously produced 458 
molecules127; and how a robotic ‘interrogator’ maintained the viability and organ-specific 459 
functions of eight vascularized, two-channel organ chips (intestine, liver, kidney, heart, lung, 460 
skin, blood–brain barrier and brain) for 3 weeks in culture 128. 461 
 462 
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The study of prodrugs129, which are metabolized by the body from inactive to active 463 
compounds, could benefit, as could the development of novel compounds which that rely on 464 
(or cause) bioactivation130. Slow release mechanisms (e.g. slow-release painkillers and 465 
contraceptive injections or implants), or compounds produced by non-traditional methods such 466 
as synthetic biology or genetic engineering, could also be extensively assayed for unexpected 467 
side effects. Coupling these types of new molecular technologies with powerful computational 468 
modeling tools, including quantitative systems pharmacology (QSP)131, machine learning13, and 469 
artificial intelligence (AI)132, could offer novel and helpful insights for current toxicological 470 
assessment. For example, capecitabine and tegafur (anticancer prodrugs) have been shown to 471 
be effective in a multi-organ pneumatic pressure-driven platform133, and recently Boos et al134 472 
used a hanging-drop organoid system to test how products metabolized by human liver 473 
microtissues affect embryoid bodies. The prodrug cyclophosphamide (activated by cytochrome 474 
P450) was added to the system and a 50% drop of embryoid differentiation seen, 475 
demonstrating how powerful synergistically engineered microfluidic systems can be not only 476 
for prodrug investigation, but also embryotoxicity in this case. 477 
 478 
Challenges with linking systems include how to: scale the organs of interest (e.g. allometrically, 479 
based on body size, or metabolically24); model fluid flow dynamically through the system and 480 
scale flow appropriately for each tissue23; supply all tissues with adequate growth factors and 481 
culture medium support (for example via a blood surrogate culture medium7 or by separation 482 
of cultures by endothelial barriers135); and design and fabricate these complex systems. One 483 
approach to linking systems that avoids many challenges faced with physically linking organ 484 
cultures involves functional coupling such as running media through physically separate 485 
systems sequentially to model multi-organ ADME. In the case of Vernetti et al136, this approach 486 
showed that organ-specific processing of the tested compounds was consistent with clinical 487 
data, and additionally uncovered that a liver-bioactivated microbiome metabolite crosses the 488 
blood-brain barrier using a neurovascular unit OoC137,138. 489 
 490 
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A number of physically linked systems via microfluidics and pneumatic or peristaltic pump 491 
mechanisms have been published (Figure 3) and include systems that have revealed, for 492 
example, novel mechanisms of aristolochic acid nephrotoxicity28, the metabolic coupling of 493 
endothelial and neuronal cells in the neurovascular unit139, and inflammatory crosstalk between 494 
the gut and liver140. For example, Chen et al140 examined an integrated gut-liver transwell OoC 495 
and showed that modulation of bile acid metabolism was seen in the linked system. 496 
Meanwhile, in an inflammatory state (modeling endotoxemia by increasing circulating 497 
lipopolysaccharide levels), hepatic biotransformation and detoxification pathways showed 498 
changes, highlighting that even relatively simple OoC models can give valuable information on 499 
organ interactions. 500 
 501 
Additionally, a number of multi-organ systems demonstrating utility in toxicology and disease 502 
modeling applications are appearing in the literature, including systems modeling homeostatic 503 
mechanisms32,141, hepatic metabolism and off-target cardiotoxicity34,142, and the female 504 
reproductive tract and menstrual cycle143 that reproduced a 28 day hormonal cycle in a 505 
platform including ovarian tissue, fallopian tube, uterus and cervix, but also included a liver 506 
module for reproductive toxicology utility (Figure 3A). Synergistically engineered multi-tissue 507 
organoid-based platforms linked by microfluidics are also joining the expanding cadre of multi-508 
organ OoC tools47,133,144,145. Importantly, many of these systems incorporate a variety of real-509 
time assays and biosensors for ongoing cell health and function readouts and can support 510 
extended cell culture (<28 days), allowing chronic and repeated testing of compounds for 511 
systemic toxicity evaluation35,146. Some of these linked systems are becoming more broadly 512 
available to researchers either through contract research organization (CRO)-based services or 513 
purchase of off-the-shelf systems, although the latter are generally simpler organoid-based 514 
higher throughput multi-well plate systems. Manufacturing the more complex OoC systems 515 
designed by engineering labs is still an obstacle to widespread implementation in biomedical 516 
labs. 517 
 518 
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[H1] Replication, validation and commercialization 519 
As OoCs become increasingly commercially available, reproducibility of the technology at 520 
multiple sites is becoming critically important. Negotiating legal frameworks to facilitate sharing 521 
of proprietary information and technologies between organizations can can be lengthy. 522 
Meanwhile, sometimes critical exchange of reagents and trained personnel can become costly, 523 
and unexpected obstacles can emerge from simple processes such as shipping cells and 524 
resources. Some questions that arise from these obstacles include: should cells be shipped in 525 
differentiated or undifferentiated forms? Should platforms be seeded with cells, or should the 526 
recipient fabricate the systems from shared molds instead? Can cells be shipped in OoC plates 527 
in a frozen state and simply thawed prior to use by end-users? Thorough consideration of the 528 
most straightforward processes can become complex and expensive. 529 
 530 
[H2] Robust, reproducible, reliable platforms 531 
The US government has provided almost a decade of support for OoC development, and 532 
although the DARPA ‘body-on-a-chip’ program has now ended other federal agencies continue 533 
to support US-based OoC development, and agencies in Europe and elsewhere are also 534 
supporting OoCs (Box 1). In particular, the National Center for Advancing Translational Sciences 535 
(NCATS) has created two new programs since 2016 that focus on creation of reproducible, 536 
reliable, and automated systems that are accessible to the wider community. The Tissue Chip 537 
Testing Centers (see Related links) initiative began in 2016 to support two independent centres 538 
charged with onboarding developers’ tissue chips, monitoring reproducibility of assays and 539 
outcomes, and investigating additional parameters that are of use to the community. The first 540 
publication addressing independent validation of a kidney proximal tubule model was recently 541 
published147 and a number more are forthcoming. To encourage the development of robust 542 
automated systems with smaller laboratory benchtop footprints, the NCATS Tissue Chips in 543 
Space program also promises advances for the technical development in the field (Box 1). These 544 
programs, plus commercial pressures, are pushing the move towards more ‘turn-key’ OoCs to 545 
help reduce or remove the need for the specialized infrastructure and highly-skilled personnel, 546 
which is currently often required for OoC implementation. 547 
 548 
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[H2] Commercial considerations and hurdles 549 
[H3] Increasing throughput: Most complex non-organoid tissue chips are currently very low 550 
throughput, where only dozens of replicates (at most) can be performed at any one time. 551 
Consequently, during the early stages of drug discovery, at which many thousands of potential 552 
hits can be identified in a short time-frame through standard high-throughput screening assays, 553 
the use of such chips is likely to be considered cost- and time-prohibitive for pharmaceutical 554 
companies at present. Technological advances to create more automated, miniaturized OoC 555 
systems that can become ‘turn-key’ technologies for facile use will be crucial to increasing 556 
throughput and the number of replicates per platform. 557 
 558 
[H3] Scaling up of reliable manufacturing processes: One difficulty with many OoCs is how to 559 
scale-up system manufacturing to an industrial pace. Most early OoC designs are bespoke and 560 
fabricated in-house at the developers’ institutions, where fabrication is limited by cost and 561 
availability of both manufacturing equipment and personnel. Therefore, academic laboratories 562 
should focus on early quality control of the chips produced in-house, to ensure reliability and 563 
reproducibility before scale-up can occur. This means careful compilation of standard operating 564 
procedures for chip design and creation, and designing clear quality control procedures that can 565 
be easily followed at other laboratories or manufacturers. Since most academic laboratories are 566 
not equipped for scale-up of production, the creation of spin-off or start-up companies, or 567 
formation of partnerships with manufacturing firms to mass-produce chips, becomes 568 
necessary. At this stage, it would be extremely useful for all manufacturers to conform to Good 569 
Manufacturing Practice guidelines (see Related links) such as those set forth by the US FDA, 570 
which cover issues including equipment verification, process validation, sanitation and 571 
cleanliness of manufacturing facilities, and appropriate training of personnel. While this 572 
guidance is to ensure the safety and reliability of manufacturing processes for foods, drugs, and 573 
devices for medical use, and is therefore not necessary for OoC manufacturing, it would still 574 
provide excellent standards for reliability of chip production across all fields and help to broadly 575 
increase confidence in the systems. In order to increase end-user confidence in the reliability 576 
and fidelity of mass-produced platforms, additional considerations should be taken that all 577 
biological assays are created on chips under Good Laboratory Practices, as this is critical for 578 
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preclinical toxicology testing and has been identified as a major reason for drug development 579 
attrition rates148. In addition, there is a need for independent “qualification” labs to test OoCs 580 
and their usage with available cell types, much like the NCATS Tissue Chip Testing Centers (see 581 
Creating a “Body on a Chip”) or the European Union Reference Laboratory for Alternatives to 582 
Animal Testing European Centre for the Validation of Alternative - EURL ECVAM (see Related 583 
links). 584 
 585 
[H3] Onboarding versus outsourcing: Due to the expense and complication of technology 586 
transfer for some OoCs, developers may face the decision between supplying a commercial 587 
product for purchase to be used independently in a customer’s laboratory, or offering services 588 
through a CRO to OoC consumers. If researchers decide to commercialize their OoC platforms, 589 
technology transfer and onboarding processes should become seamless, reliable and 590 
standardized for every customer. Meanwhile, retaining the personnel, infrastructure and 591 
resources necessary for OoC use within a CRO-based service means customers should expect 592 
high standards of the research produced. However, the flexibility and adaptation of the chips 593 
for specific contexts of use may be limited because CROs may not offer particular assays or 594 
services. As this burgeoning field is still young, many developers and companies are choosing to 595 
adopt aspects of both business models. Some offer OoC devices that can be onboarded 596 
relatively easily but may need specialized equipment and/or extensive technical support. Other 597 
CROs perform experiments in-house in collaboration with academic or industry researchers to 598 
help advance continuing R&D on the system. 599 
 600 
[H3] Managing expectations: While the potential of OoCs is exciting, the technology is at an 601 
early stage, so providing realistic caveats and limitations to potential consumers is critical to 602 
avoid overselling its current capabilities. Some challenges faced within the field may be 603 
resolved over the next decade or so – issues with cell sourcing will continue to be addressed as 604 
the stem cell field matures, for example. Other limitations may take longer to resolve – for 605 
example, reduction and refinement of animal use are laudable and achievable aims and are 606 
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within the realm of possibility already, but full replacement of animals in drug development is 607 
generally seen as unlikely in the near future. 608 
 609 
One approach to managing expectations has been employed by government funding agencies 610 
in the US where creating partnerships between research and regulatory agencies, such as the 611 
NIH and FDA, over the last decade has allowed regulators access to OoC developers and their 612 
unpublished data to help inform system development. Conversely, it has enabled researchers 613 
to design useful platforms to provide data for regulatory assessment. This has led to familiarity 614 
of the technology among the regulatory community in the US, which ultimately can help pave 615 
the way for OoC data inclusion in IND (Investigational New Drug) [G] and NDA (New Drug 616 
Application) [G] packages in the future. 617 
 618 
[H2] Validating organs-on-chips 619 
As OoCs continue along a path towards widespread commercialization, validation must be 620 
considered. Importantly, the term ‘validation’ means different things to various stakeholders, 621 
but could be considered as involving three stages or principles149. First, physiological validation 622 
could be defined in the context of ‘analytical performance’, including addressing features such 623 
as sensitivity, specificity and precision (essentially reproducibility). This validation step is 624 
necessary to create a tissue chip that appropriately and reliably mimics the tissue of interest 625 
and responds in relevant ways to compounds of known action or toxicity, and it should be 626 
performed by OoC developers. Second, qualification or validation to show biological in vivo 627 
relevance should come next, although there is debate in the field as to whether animal or 628 
human responses should be used for this stage. Animal responses are broadly used in current 629 
drug development, which supports the argument that they should be the ‘gold standard’ for 630 
OoC responses to be compared against. Conversely, predicting human responses is the aim for 631 
the field, which supports the focus on generation of human responses on OoCs. Reproducibility 632 
and setting the standards for qualification currently fall under the remit of, for example, the 633 
NCATS Tissue Chip Testing Centers. The third stage, industrial validation, or OoC adoption by 634 
industry and regulatory agencies, will involve the generation of data from proprietary 635 
compounds and submission of that data to regulatory agencies. All of these stages of validation 636 
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are currently underway. In the US, the FDA has also partnered with a number of OoC 637 
companies to get hands-on experience with OoC data, as they expect this type of data to be 638 
submitted to them in the near future. 639 
 640 
Taken together, the three stages/principles of validation/qualification described above will help 641 
address international guidelines for novel methods, for example the Organisation for Economic 642 
Co-operation and Development (OECD) Guidance Document on the Validation and International 643 
Acceptance of New or Updated Test Methods for Hazard Assessment (see Related links) These 644 
guidelines describe necessary assay details for validation such as the rationale, the endpoints 645 
and limitations, protocols, variability, performance with reference and known chemicals, and 646 
comparisons to existing assays. Importantly, the OECD guidelines also state that data 647 
supporting the validity of the method must be available for review. To address this need for all 648 
stakeholders, the NIH’s NCATS also funds an MPS Database, which is tasked with integrating all 649 
the data from the Testing Centers, as well as data from a number of other NIH-funded 650 
developers, FDA users, and commercial OoC suppliers. This centralized database acts as a public 651 
repository for a broad range of OoC data and will prove useful for developers, industry and 652 
regulatory bodies over the coming years, with a recent report highlighting functionality for data 653 
visualization, inter- and intra-study reproducibilities and power analyses calculations 150. 654 
 655 
Additionally, underpinning the needs of the above validatory steps, the accurate 656 
standardization of methodologies used for generating empirical data should be considered. The 657 
term ‘standardization’ brings on new challenges with respect to what ‘standardization’ means 658 
for either technical, analytical or biological aspects of OoCs. So, ‘performance standards’ should 659 
be established for the analytical validation and biological qualification of OoCs. To this end, the 660 
deposition of technical, analytical and biological data into the MPS-Database will help set some 661 
of the standards, reducing the need for each user to develop their own methodologies, assays 662 
and analytical methods. At the same time, many US government-funded researchers are 663 
working with regulatory and industrial end-users to evaluate what should be considered 664 
accepted metrics that are translatable to other laboratories and applications. 665 
 666 
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[H1] Emerging opportunities and prospects 667 
There are multiple stages at which OoC platforms could be implemented in drug discovery and 668 
development, and the platform type may differ depending on the stage (see Figure 1). High-669 
throughput plate-based OoCs with relatively simplistic (but cheap and fast to produce) tissue 670 
constructs could prove useful for target identification, lead selection and lead optimization. 671 
Low- to medium-throughput OoC platforms that model more complex tissue-tissue or organ-672 
organ interactions could be more useful for preclinical single or double organ toxicity and 673 
efficacy studies. Multi-organ systems – while perhaps the most complex and expensive to 674 
develop – offer promise for reducing the need for animal studies and for use in parallel with 675 
phase I and II clinical trials. Finally, OoC platforms from patient stem-cell-derived sources could 676 
be used during later clinical trial phases (III and IV) as well, for in vitro therapeutic testing 677 
before in vivo administration, or for concurrent monitoring of approved therapeutics. 678 
Ultimately, the potential safety and efficacy of a drug or drug candidate could be evaluated 679 
using OoCs in generic, or even individualized, human platforms, giving “first-in-human” testing 680 
a new connotation. 681 
 682 
Coupling OoC technology with techniques such as gene editing151 (particularly when a series of 683 
disease-relevant mutations are introduced onto a single genetic background) offers powerful 684 
ways to increase the predictive power of these tools further in disease modeling and toxicology. 685 
We also see opportunities to discover and validate clinically-translatable biomarkers by creating 686 
datasets to correlate in vitro OoC readouts with clinical outcome measures. For example, using 687 
OoCs to produce ‘omics’-based (and even real-time) readouts could promote the identification 688 
and evaluation of appropriate endpoints surrogate to those in the clinic, which could provide 689 
valid and reliable measures of change in human subjects. These endpoints and readouts could 690 
be quantified and assessed for clinical benefit and compared to traditional enzymatic, 691 
biochemical or histopathological assays, as well as offer ways to assess both short- and long-692 
term clinical changes. Ultimately, the use of OoC readouts detailing changes in molecular 693 
signatures that have been validated against traditional methods and demonstrated clinical 694 
relevance could become a common practice in drug development. 695 
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 696 
In order to help smooth the adoption and implementation of OoCs in the drug development 697 
process, continued engagement and discussions with OoC developers and end-users is critical, 698 
as is engaging with regulatory bodies. A 2017 report predicted that the global OoC market could 699 
grow by 38% per year to become a US$117M/year industry in 2022 (based on market analysis 700 
by Yole Développement) – with the potential to become a multi-billion dollar industry. In 701 
support of this predicted growth and the utility of OoCs at various stages of drug development, 702 
a recent anaylsis predicted up to a 26% reduction in R&D costs in the pharmaceutical industry 703 
by adopting OoC technology152, and it is anticipated that OoC data will be included in IND and 704 
NDA submissions to the US FDA in the near future. 705 
 706 
There is optimism that OoC systems may one day outperform traditional models, making the 707 
understanding of human diseases and development of drugs to treat them more rapid, 708 
efficient, and cost-effective, and in so doing replace, reduce and refine (the “3Rs”) the use of 709 
laboratory animals. Nevertheless, much work remains to address the challenges discussed in 710 
this article, and thereby determine and realize the potential of this technology. According to 711 
the 2018 Gartner report (see Related links) on the hype cycle of emerging technologies, OoCs 712 
(referred to as ‘biochips’ in this report) are now in the ‘Peak of Inflated Expectations’ phase. 713 
Disillusionment and a stall in progress often occurs after this phase because the technology fails 714 
to live up to the preliminary, and often inflated, expectations, before the field recovers and 715 
productivity resumes, with more modest expectations. Therefore, the aim for emerging 716 
technologies is to reach this productive plateau as quickly as possible, when 20-30% of the 717 
potential audience has adopted the innovation. Right now, this is estimated to be 5-10 years for 718 
OoCs. It will take the coordinated global efforts of the OoC community to help this technology 719 
reach that potential global audience and ultimately, help transform science, medicine, and 720 
patients’ lives.  721 
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[bH1] Box 1: Collaborative tissue chip development efforts 722 
In 2010, the US Food and Drug Administration (FDA) and the US National Institutes of Health 723 
(NIH) created a Joint Leadership Council to help speed the translation of biomedical discoveries 724 
at the laboratory bench to commercial availability of new therapeutics. Under this mandate, 725 
the Advancing Regulatory Science program was initiated, with awards issued to address 726 
distinct, high priority areas of regulatory science. Based on the promise from these funded 727 
projects, from which the seminal lung-on-a-chip work was published8, the NIH and FDA 728 
partnered with the Defense Advanced Research Projects Agency (DARPA) to fund two 5-year 729 
programs for the development of OoCs. The NIH program, called “Tissue Chips for Drug 730 
Screening” (see Related links), awarded funding to develop 3D microsystems to represent 731 
multiple tissue types and also concurrently funded a program to explore the use of stem cells 732 
and progenitor cells to differentiate into the multiple cell types that would be needed to 733 
populate the microsystems. DARPA’s MPS program (see Related links) focused on developing a 734 
reconfigurable platform of at least 10 human organs or tissues in an integrated system that 735 
could mimic and replicate biological crosstalk between tissues. While both initial programs 736 
ended in 2017, the NIH continues to offer funding for further development of OoCs in an 737 
expanding array of programs, including for disease modeling, inclusion of immune factors, 738 
modeling of Alzheimer’s Disease, use in the context of clinical trials, and as part of the NIH Help 739 
End Addiction Long-term (HEAL) initiative (see Related links) to address the US opioid epidemic. 740 
 741 
The FDA has offered advice and guidance from a regulatory standpoint for the past decade, and 742 
recently signed Memorandums of Understanding with a number of commercial tissue chip 743 
companies to on-board the technology to FDA laboratories. Additionally, the IQ Consortium 744 
(see Related links), a non-profit organization consisting of pharmaceutical and biotechnology 745 
company representatives, partnered with US government funding agencies in 2016 to add end-746 
user stakeholder perspectives to the field. The IQ Consortium recently published a series of 747 
manuscripts on the characterization and use of OoC sytems in safety and toxicity profiling 748 
applications 56,153 and for modeling skin154, lung155, the GI tract156, kidney157 and liver 158. 749 
 750 
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In Europe, the Institute for human Organ and Disease Model Technologies (hDMT, see Related 751 
links), headquartered in the Netherlands, leads the way on integrating state-of-the-art human 752 
stem cell technologies with biotechnical fields to support the development and validation of 753 
human organs and disease models-on-chip. The hDMT consortium helped co-ordinate one of 754 
the European Union’s Horizon 2020 research and innovation programs termed Organ-on-Chip 755 
Development (ORCHID, see Related links), and in late 2018 launched the new European Organ-756 
on-Chip Society (EUROoCS, see Related links) that will encourage development and 757 
coordination of tissue chip research in Europe. Other countries are following the hDMT 758 
example and are establishing similar organ-on-chip networks in Israel, UK, the Scandinavian 759 
countries and Switzerland. 760 
 761 
One key tenet of collaborative partnerships for tissue chip development has been the 762 
involvement of different stakeholders to help advance each of their missions. For example, 763 
partnership of tissue chip developers with the Comprehensive in vitro Proarrhythmia Assay 764 
(CiPA, see Related links) initiative helps provide tools to fulfill CiPA’s mission of engineering 765 
assays for assessment of the proarrhythmic potential of new drugs with improved specificity 766 
compared with current assays, while demonstrating the utility of tissue chips for toxicity 767 
screening. 768 
 769 
Another collaboration between the NIH and the Center for Advancement of Science in Space 770 
(CASIS, see Related links) allows researchers to use the microgravity environment on the 771 
International Space Station (ISS) to conduct biomedical research. The program, which partners 772 
with the International Space Station National Laboratory (ISS-NL), is using microgravity as a tool 773 
to investigate Earth-based disease pathologies such as formation of kidney stones that would 774 
otherwise be difficult or take too long to model on Earth. Moreover, researchers and space 775 
payload developers work collaboratively to adapt OoC platforms and make them robust enough 776 
for rocket launch, spaceflight, integration into ISS facilities, and splash-down. This is leading to 777 
advances in the technical engineering of robust platforms capable of higher throughput (>24 778 
replicates running concurrently) with a much smaller footprint. The systems are turn-key 779 
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enough to be “astronaut-proof”, meaning that non-scientist workers (in this case astronauts, 780 
most of whom are not trained in laboratory techniques) can perform the necessary 781 
interventions – both in space and in the future on Earth in a variety of applications159. 782 
  783 
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[bH1] Box 2: Cell sourcing for 3D tissue engineering 784 
The common aphorism of “all models are wrong but some are useful” is apt when considering 785 
cell sourcing for microphysiological systems (or any bioengineered tissue models). No cell 786 
source is perfect; many have serious caveats; but even the most problematic cell source can 787 
provide useful information if used appropriately based on the question being asked. Cells 788 
seeded in tissue chips come from three main sources: commercially available cell lines; primary 789 
cells from human donors; and induced pluripotent stem cell (iPSC)-derived sources. 790 
 791 
[bH2] Commercially available cell lines: Cell lines should have extensive validation of purity and 792 
viability when received from reliable sources (such as the American Type Culture Collection) 793 
and are often proliferative as well as easy to culture and transfect. These cells have clear and 794 
reliable culture protocols, generally respond in stable and predictable ways and will likely 795 
contribute to high reproducibility. Commercially available cells can be excellent sources of hard-796 
to-find cell types, or when primary and iPSC sources are unavailable. However, these cell lines 797 
are approximations for the primary cell types found in vivo and should be periodically evaluated 798 
to see how far from the primary cell phenotype the new generations are straying. 799 
 800 
[bH2] Primary cells: The clear advantage of using cells from human donors is that the cells 801 
capture the phenotype (presumably genetically and functionally) of the mature adult state. 802 
Primary cells can model disease pathologies when sourced from donors with certain diseases 803 
and can accurately reflect clinical population variance in their phenotypes. However, because 804 
genetic and epigenetic differences arise during a donor's lifetime, variability between donors or 805 
batches can be hard to identify and track. For some primary tissues (for example: neural cells), 806 
access from donors may not even be possible. In many cases, primary cells are available 807 
because the tissue has been removed or biopsied for diagnostic purposes and can be displaying 808 
pathological phenotypes. Primary cells also require specialized culture and media to retain their 809 
phenotypes, which can be problematic in linked tissue chip systems, as a common media could 810 
prove suboptimal for the different tissues. Finally, adult stem cells grown as organoids (for later 811 
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seeding in OoCs) only represent the epithelial component of the tissue, not the stroma or 812 
vasculature, limiting their application. 813 
 814 
[bH2] iPSCs: Stem cell-derived sources are a potential solution to cell sourcing difficulties for 815 
tissue chips because they are potentially infinitely renewable and can be from either healthy or 816 
diseased populations. These iPSCs provide huge potential for populating tissue chips because 817 
individuals could have platforms created that model their tissues and disease phenotypes. This 818 
also allows creation of isogenic cell lines for genetic disorders, in which the resulting iPSCs can 819 
be genetically engineered to either harbor the disease-specific mutation or not, allowing 820 
opportunities to study the genetic impact of a disorder with unparalleled specificity. 821 
 822 
Drawbacks of iPSC-derived tissues include the immature or fetal phenotypes (for example: 823 
cardiomyocytes; kidney; and liver) of the cells, which can limit their utility. The time and 824 
resources needed for creation and passaging of cell lines, and later differentiation, is long (nine 825 
months or more for some neural tissues) and expensive compared to the ease of buying 826 
commercially available cells. Also, cells may retain an ‘epigenetic memory’ of their donor 827 
tissues160 depending on the number of passages, which can limit directed differentiation for 828 
specific tissues. 829 
  830 
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Figure legends 831 
Figure 1 |Utility of OoCs in a variety of stages of drug development 832 
Drug development is a dynamic environment for data feedforward and feedback between 833 
multiple stages and processes, being described as a ‘dynamic map’ 161. These dynamic maps 834 
provide a framework for understanding modern drug development and include activities and 835 
processes such as Lead Identification, Clinical Research and Development and Regulatory 836 
Review. OoCs can be informative in a number of these neighborhoods. On this schematic of an 837 
OoC surrounded by the multiple stages and processes of drug development, green components 838 
represent the known current or shortly predicted use of OoCs and blue components represent 839 
the possible and predicted utility. Many OoCs are currently at the ‘Basic science research stage’. 840 
Use of OoCs in the ‘Medical landscape’ stage includes use for precision medicine and patient-841 
specific treatments. ‘Clinical research and development’ use would include patient subgroup 842 
stratification and projects under the NIH “Clinical Trials on a Chip” program, as an example. 843 
‘Regulatory review’ refers to IND and NDA data. ‘Post marketing’ refers to adverse drug 844 
reaction reporting and drug repurposing efforts. References are included for examples of OoC 845 
use in these areas. [PR: permissions for need to be included]. 846 
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Figure 2 | Examples of features and platform designs for organs on chips  848 
Diverse platform design and key design features for organs on chips allow a broad range of data 849 
readouts which can be used for computational modeling as part of the drug discovery process. 850 
A broad diversity of tissue platforms highlights key common features – the 3-dimensions for 851 
tissue culture, inclusion of multiple cell types, and modeling of biomechanical forces that 852 
recreate the in vivo environment. 853 
a) Transwell systems allow barrier modeling and fluid flow across a permeable membrane for 854 
media exchange and cell-cell interaction. In this example, Caco2 and mucus-855 
secreting HT29-MTX intestinal cells create the gut apical side, with immature dendritic cells 856 
seeded on the basal side and left to mature, creating a barrier model of the gut. On the 857 
right, barrier function of transwells can be measured by trans-epithelial electrical 858 
resistance (TEER) or secretion of e.g. mucin from cells in both single and linked OoCs. 859 
Adapted with permission from 140. 860 
b) Platforms with diamond-shaped cell chambers (2mm wide by 1mm high) allow for seeding 861 
with human endothelial colony-forming cell-derived endothelial cells (ECFC-EC, in green) 862 
which self-organize into perfusable microvasculature, with cell media supplied via 863 
microfluidic channels flowing from bottom to top. Seeding with colorectal cancer cells 864 
(HCT116 cells, in blue) forms vascularized microtumors which can be used to screen 865 
chemotherapeutics for safety and efficacy. Histology allows clear localization and 866 
visualization of cell interactions, such as the vascularization of microtumors and the 867 
perfusion of media through the system (rhodamine B dextran, in red). Adapted with 868 
permission from 29. 869 
c) A vascularized liver acinus model (vLAMPS – left) consisting of cells in collagen sandwiched 870 
between three glass layers allows 3D layering of multiple liver cell types representing the 871 
liver acinus. (Right) Oxygen zonation can be computationally modeled by calculating the 872 
rate of media flow in the microfluidic channels, creating 3 distinct zones (oxygen rich; 873 
intermediate; and oxygen-poor) on the platform which recreate the liver sinusoid and 874 
establish a metabolic gradient similar to that seen in vivo. LECM; liver extracellular matrix. 875 
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PET; polyethylene terephthalate. LSECs; liver sinusoidal endothelial cells. Adapted with 876 
permission from 62. 877 
[PR: permissions for panels a, b, and c need to be included]. 878 
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Figure 3 | Examples of linked multi-organ systems, which can help understand systemic or off-880 
target drug effects and create “body-on-a-chip” systems. The modules and media can be 881 
linked by (A) pneumatic or electromagnetic pumps, (B and C) peristaltic flow, or (D) media 882 
circulated by hydrostatic flow driven by gravity. 883 
a) (Left) This female reproductive system MPS contains 5 tissue modules (ovary, cervix, 884 
uterus, fallopian tube and liver) and models the hormonal profile of the female 885 
menstrual cycle and pregnancy which can be useful for assessing female reproductive 886 
toxicity. (Right) The modules are linked by a complex series of internal valves and pumps 887 
under the tissue construct inserts and flow of tissue-specific media and hormones are 888 
driven by pneumatic pumps powered by electromagnets. Adapted from 143. 889 
b)  (Left) A simplified schematic of a linked multi-organ system for investigating 890 
doxorubicin-induced toxicity on liver, heart, bone, and various other tissues e.g. brain. 891 
The platform consists of individual tissue constructs cultured in multiple modular 892 
‘inserts’, set into a platform with the same footprint as a standard 6-well laboratory 893 
plate. In this example, 4 tissue types can be replicated in triplicate on a single plate. 894 
(Right) Schematic of the side view of the platform. Underneath each tissue insert lies a 895 
permeable membrane lined with endothelial cells, perfused by a recirculating vascular 896 
medium driven by peristaltic pump. The system allows for optimal cell culture for each 897 
tissue type as well as inclusion of common circulating factors such as immune cells, 898 
hormones and exosomes. Adapted with permission from 162. 899 
c) A robotic system with inbuilt microscope, peristaltic pump, and automatic fluid handling 900 
named the ‘Interrogator’ can house up to 10 OoCs for PK/PD and PBMK modeling. 901 
Reproduced with permission from 128. 902 
d) This commercially available multi-organ system from Hesperos Inc. cultures liver, cardiac 903 
and skeletal muscle and neurons on a microfluidic chip. Each tissue module is cultured 904 
on a plate modified by proprietary surface chemistries to help cells adhere to the 905 
surface and act as ECM, and media reservoirs contain a serum-free common medium 906 
which is gravity-fed by placing the chip on a laboratory rocker. Cardiac, skeletal and 907 
neuronal modules contain microelectrode arrays (MEA) to stimulate and record activity 908 
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in tissue subtypes. Adapted with permission from Schaffer C (November 30 2017) “3D-909 
Bioprinting Conference Showcases Versatility” Genetic Engineering and Biotechnology 910 
News magazine Vol 37, No 21. Published by Mary Ann Liebert Inc. publishers. 911 
https://www.genengnews.com/magazine/305/3d-bioprinting-conference-showcases-912 
versatility/ 913 
[PR: permissions for panels a, b, c, and d need to be included]. 914 
.  915 
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Glossary 916 
 917 
extracellular matrix (ECM) – supporting network of macromolecules providing structural and 918 
biochemical support to surrounding cells. Promotes cell adhesion and cell-cell communication 919 
and produces biochemical cues for tissue growth and maintenance. The ECM is tissue-specific 920 
and in animal tissues consists of fibrous elements (collagen, elastin), and links proteins (laminin, 921 
fibronectin) and other molecules. 922 
 923 
hydrogels - highly absorbent and hydrophilic biocompatible 3D polymer networks used to 924 
contain cells or drugs for tissue engineering applications. Can consist of natural (collagen, 925 
gelatin, agarose) or synthetic components and respond to environmental conditions such as pH. 926 
May have both liquid and solid properties. Other uses include wound dressings, contact lenses. 927 
 928 
multi-electrode arrays (MEAs) – arrays of 10-1000s of tightly spaced microelectrical sensors 929 
designed to record from single cells to networks of cells at sub-millisecond timescales. Can also 930 
be used to stimulate cells with precise spatial and temporal characteristics. Used in electrically-931 
excitable tissues such as cardiac, muscular, neural. 932 
 933 
pharmacokinetic/pharmacodynamic (PK/PD) modeling – integration of pharmacokinetics (PK – 934 
movement of drugs through the body) and pharmacodynamics (PD – body’s biological response 935 
to drugs) into a mathematical model describing dose-concentration-response relationships. Can 936 
be used to predict effect and efficacy of drug dosing over time. 937 
 938 
physiologically-based pharmacokinetic (PBPK) modeling – mathematical modeling of body 939 
compartments (predefined organs or tissues) combined with known parameters of 940 
concentrations, quantities and transport between compartments used to predict absorption, 941 
distribution, metabolism and excretion (ADME) of synthetic or natural chemical substances 942 
within the body. 943 
 944 
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IND (Investigational New Drug) – An application submitted to the US Food and Drug 945 
Administration (FDA) to administer novel drug to humans. The first step in the drug review 946 
process, which includes information on animal studies, manufacturing protocols, and clinical 947 
and personnel protocols. Data gathered becomes part of the New Drug Application (NDA). 948 
 949 
NDA (New Drug Application) – An application submitted to the US FDA requesting permission 950 
to sell and market a drug in the US. Information submitted includes data from the IND and is 951 
reviewed for safety and efficacy, benefit versus risks, appropriate labelling information, and 952 
manufacturing and processing methods. 953 
  954 
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Related Links 955 
Defense Advanced Research Project Agency (DARPA) funded linked 10 organ system: 956 
https://www.darpa.mil/program/microphysiological-systems  957 
 958 
US National Institutes of Health (NIH), FDA and DARPA funded development of tissue chips to 959 
advance regulatory sciences: https://www.nih.gov/news-events/news-releases/nih-fda-960 
announce-collaborative-initiative-fast-track-innovations-public  961 
 962 
Tissue Chip Testing Centers: https://ncats.nih.gov/tissuechip/projects/centers 963 
National Center for Advancing Translational Sciences (NCATS) Tissue Chips in Space: 964 
https://ncats.nih.gov/tissuechip/projects/space  965 
 966 
Good Manufacturing Practice guidelines: https://www.ecfr.gov/cgi-bin/text-967 
idx?SID=cb7c830642b365274d824a432e118e77&mc=true&node=pt21.8.820&rgn=div5 968 
 969 
European Union Reference Laboratory for Alternatives to Animal Testing European Centre for 970 
the Validation of Alternative (EURL ECVAM): https://ec.europa.eu/jrc/en/eurl/ecvam 971 
 972 
Organisation for Economic Co-operation and Development (OECD) Guidance Document on the 973 
Validation and International Acceptance of New or Updated Test Methods for Hazard 974 
Assessment: https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd-gd34.pdf 975 
 976 
Organs on chips - 2017 market overview analysis by Yole Développement: 977 
http://www.yole.fr/OrgansOnChips_Market.aspx#.XIP6dVNKiV4 978 
 979 
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IQ Consortium: https://iqconsortium.org/ 984 
 985 
human Organ and Disease Model Technologies (hDMT): https://www.hdmt.technology/ 986 
 987 
ORCHID: https://h2020-orchid.eu/ 988 
 989 
Comprehensive in vitro Proarrhythmia Assay (CiPA): http://cipaproject.org/ 990 
 991 
The Center for Advancement of Science in Space (CASIS): https://www.iss-casis.org/ 992 
  993 
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Table 1. Key features of two-dimensional and three-dimensional engineered tissues. 994 





Grown on rigid flat surfaces, 
often as a cellularly 
homogeneous monolayer 
Embedded in 
hydrogels/suspended in 'hanging 
drops', and left to self-organize 
into multiple cell types 
Multiple relevant cell types seeded 
into engineered chambers with 
perfusion and/or biomechanical 
forces included 
Production 
complexity and speed 
Generally straightforward 
and fast (minutes-days) 
Generally straightforward, but 
slower (days-weeks) depending 
on cell sources 
Variable complexity (depends on 
platform design), slower (days to 
weeks) depending on cell sources 
and required tissue maturation 
metrics 
Level of control over 
cell architecture  High Very low High 
Maturation of iPSC-
derived cells allowed 
by platform* 
Immature Improved but still highly immature 
Platform designs can improve and 
encourage cell maturity164 
Resulting cell 
morphology 
Unnatural, with limited ECM 
composition and contact with 
cells 
Similar size and shape to in vivo, 
allows relevant ECM interaction 
during cell proliferation 
Similar size and shape to in vivo, 
allows relevant ECM interaction 
throughout cell lifetime 
Diffusion of signal 
factors and nutrients Short distances possible 
Ineffective transport to interior 
can cause cell death or 
immaturity  
Allows precisely controlled temporal 
and spatial gradients 
Vascularization or 
perfusion? 
Not possible, generally 
perfusion via media change 
Depends on cell types but likely 
creates non-functional vessels; 
externally perfused; can include 
fluid flow across tissue surfaces 
Yes - by microfluidic channels or 




Possibly, depending on 
tissue165,166 
Depends on platform design; 
generally low to medium throughput 
On-platform assay 
and analysis difficulty 
Low difficulty, easy access to 
cells and readouts 
Tissue function analyses possible; 
cell separation not possible 
Real-time tissue/organ function 
analyses possible 
Variability and in vivo 




Low variability and relevance 
- simple, homogeneous 
cultures 
Can be high variability and low 
relevance as there is little control 
over resulting cell subtypes and 
location  
Can be low variability and high 
relevance - allows high levels of 
control over cell type and placement 
*immaturity of iPSC-derived cells still a general issue995 
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Table 2 – Examples of single tissue OoCs for toxicological assessment 996 
Tissue/Organ Platform Characteristics Challenge Response Reference 
Liver “SQL-SAL” Human hepatocytes, 
stellate, immune and 
endothelial cells are layered 
in glass and PDMS 
microfluidic chip. 
Fluorescent biosensors 
included. Survival to 28 
days.  
1. Troglitazone and 
nimesulide (hepatotoxic) 
2. Trovafloxacin + LPS and 
levofloxacin + LPS (immune-
mediated hepatotoxicity) 
3. Methotrexate (fibrotic 
injury) 
4. Caffeine (negative control) 
1. Time and dose-dependent LDH release, 
apoptosis, plus decreased albumin and 
urea secretion  
2. Increased LDH release and apoptosis with 
trovafloxacin + LPS but not levofloxacin + 
LPS 
3. Increased fibrotic markers 
4. No effect 
Vernetti et al 
201661 
Liver Primary hepatocytes places 
across porous membrane 
from LSECs, +/- Kupffer and 
stellate cells. Rat, dog, 
human species comparisons 
possible.  
1. Bosentan (cholestatic) 
2. Acetaminophen 
(hepatotoxic) 
3. Methotrexate (fibrotic 
injury) 
1. Species-specific albumin decrease; 
correlated to clinical response in humans; 
bile salt transport inhibition 
2. Glutathione and ATP depletion; 
formation of ROS; decreased albumin 
secretion 
3. Lipid accumulation (steatosis) and 
fibrosis 
Jang et al 
201963 
Cardiac Self-organized iPSC-derived 
cardiomyocytes in 3D 
microfluidic device 
1. Isoproterenol (β-adrenergic 
agonist)  
2. E-4031 (hERG blocker) 
3. Verapamil (multi-ion 
channel blocker)  
4. Metoprolol (β-adrenergic 
antagonist) 
Cardiac beat frequencies in line with clinical 
data including dose-dependent changes and 
arrhythmias concordant with human 
cardiotoxicology data 
Mathur et al 
201564 
Kidney Primary human kidney 
proximal tubule epithelial 
cells seeded to form a 
lumen in microfluidic 
platform 
Polymyxin B Increased KIM-1 and injury-associated 
miRNAs 
Weber et al 
201878 
ATP, adenosine triphosphate; hERG, Human ether-a-go-go-related potassium channel; KIM-1, kidney injury molecule 1; LSECs, liver sinusoidal 997 
endothelial cells; LPS, lipopolysaccharide; LDH, lactate dehydrogenase; PDMS, polydimethylsiloxane; ROS, reactive oxygen species. 998 
 999 
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